Cxcolorectal

Cxcolorectal^® is a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancer. The test predicts the aggressiveness of the tumour, allowing the clinician to make the best decision regarding treatment for the patient. The gene signature passed a clinical study in Europe and Pacific Edge is currently refining Cxcolorectal^® to reduce cost and increase ease of delivery of the service. It is anticipated that the test will be launched in the Australasian market by Pacific Edge by mid 2012.